Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

GSK Investigational Site, Johannesburg

GSK Investigational Site, Ennerdale

GSK Investigational Site, New York

GSK Investigational Site, Gyeonggi-do

GSK Investigational Site, Milan

GSK Investigational Site, Milan

GSK Investigational Site, Monza (MB)

GSK Investigational Site, Madrid

GSK Investigational Site, Málaga

GSK Investigational Site, Santander

GSK Investigational Site, Baggiovara (MO)

GSK Investigational Site, Daegu

GSK Investigational Site, Ulsan

GSK Investigational Site, Detroit

GSK Investigational Site, Busan

GSK Investigational Site, Iowa City

GSK Investigational Site, Sacramento

GSK Investigational Site, Beijing

GSK Investigational Site, Beijing

GSK Investigational Site, Moscow

GSK Investigational Site, Changchun

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Shanghai

GSK Investigational Site, Hangzhou

GSK Investigational Site, Samara

GSK Investigational Site, Chelyabinsk

GSK Investigational Site, Novosibirsk

GSK Investigational Site, Barnaul

GSK Investigational Site, Красноярск

GSK Investigational Site, Calgary

GSK Investigational Site, Edmonton

GSK Investigational Site, Montreal

GSK Investigational Site, Aichi

GSK Investigational Site, Fukui

GSK Investigational Site, Gifu

GSK Investigational Site, Hiroshima

GSK Investigational Site, Kumamoto

GSK Investigational Site, Nagasaki

GSK Investigational Site, Tokyo

GSK Investigational Site, Lublin

GSK Investigational Site, Mysłowice

GSK Investigational Site, Łańcut

GSK Investigational Site, Gyeonggi-do

GSK Investigational Site, Barcelona

GSK Investigational Site, Barcelona

GSK Investigational Site, London

GSK Investigational Site, Newcastle upon Tyne

GSK Investigational Site, Nottingham

GSK Investigational Site, Plymouth